歐冠昇:越來越多歐洲醫藥公司查詢來港上市
港交所(00388.HK)行政總裁歐冠昇在亞洲醫療健康高峰論壇上表示,港交所在起初吸引上市的生物醫藥公司以內地企業為主,但最近收到越來越多歐洲和其他外國公司查詢有關來港上市。他指香港作為中國最國際化的城市,將來港交所會扮演關鍵角色。
在2018年上市新規生效後,港交所容許未有盈利的生物科技公司來港上市。歐冠昇稱,自從該上市改革之後,越來越多生物科技公司有興趣來港上市,目前已經有79間醫療健康公司在港上市,集資超過2,000億元,醫療健康相關上市公司的市值更超過6,000億美元,另外目前有55間這類型公司正在申請在港上市,可見行業快速增長。他說,隨著人口老化,醫療產品需求日益增加,港交所工作是要聚焦開拓所有可以聯繫資金與機遇的渠道。
歐冠昇指,生物醫藥行業發展迅速,規模龐大,上市生物醫藥公司中不少是未有盈利的公司,金融業為這個行業提供融資渠道、創造就業機會、解決公共衛生危機,是金融業貢獻實體經濟的例子。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.